Shareholders of Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights Before July 14, 2025 - Contact Levi & Korsinsky
created: June 12, 2025, 4:30 p.m. | updated: June 13, 2025, 5:02 p.m.
On July 25, 2024, Iovance announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases.
The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.
For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
33 Whitehall Street, 17th FloorNew York, NY [email protected]: (212) 363-7500Fax: (212) 363-7171https://zlk.com/SOURCE: Levi & Korsinsky, LLPView the original press release on ACCESS Newswire
2 weeks, 3 days ago: News Ticker - markets.businessinsider.com